Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: VRDN

Viridian Therapeutics, Inc.

Healthcare | Biotechnology

No licensed closing price on file for VRDN. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

Viridian Therapeutics, Inc. (NASDAQ: VRDN) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 01:10 UTC.

What Viridian Therapeutics, Inc. does

This biopharmaceutical company discovers, develops, and commercializes medicines for serious and rare diseases, focusing on autoimmune and rare disease areas where current treatments have limitations in efficacy, safety, or dosing convenience. The company's pipeline includes product candidates targeting the insulin-like growth factor 1 receptor for thyroid eye disease, neonatal Fc receptor inhibitors for multiple autoimmune disorders, and a TSHR inhibitor program for thyroid eye disease and Graves disease.

Summarized from Viridian Therapeutics, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation
Return on equity-47.44%

Revenue, margins & earnings

FY2021: net loss $79M on revenue $3M$3MFY2021FY2022: net loss $130M on revenue $2M$2MFY2022FY2023: net loss $238M on revenue $314,000$314,000FY2023FY2024: net loss $270M on revenue $302,000$302,000FY2024FY2025: net loss $343M on revenue $71M$71MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-08-20
  • 2026-08-20Chief Legal OfficerOption exercise10,000$144.1K
  • 2026-08-20Chief Legal OfficerSale-4,212$103.2K
  • 2026-08-20Chief Legal OfficerSale-10,000$245.0K
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Viridian Therapeutics, Inc. do?

This biopharmaceutical company discovers, develops, and commercializes medicines for serious and rare diseases, focusing on autoimmune and rare disease areas where current treatments have limitations in efficacy, safety, or dosing convenience.

When did VRDN last file with the SEC?

Viridian Therapeutics, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-29. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 01:10 UTC. This page is also available as JSON at /api/data?ticker=VRDN and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for VRDN and 5,000+ tickers.

Create a free account — keep VRDN
For your agent
GET /api/data?ticker=VRDN

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt